De-Extinction Unicorn Colossal Eyes $20B–$30B Funding Round

For venture capitalists, Colossal’s reported funding talks are a litmus test for the new model of deep tech platform building. The company has moved from a single, highly speculative undertaking to a diversified startup engine, with three spinouts already carrying billion-dollar price tags and a pipeline of technologies — from plastics degradation to human fertility — that can each be monetized independently. The valuation leap also raises urgent questions: can a company with limited disclosed revenue justify a $30 billion price tag, and what does the spinout strategy signal about founder and investor liquidity?

Colossal Biosciences, the controversial de-extinction startup best known for its plans to resurrect the woolly mammoth and dire wolf, is now in talks to raise funding at a staggering $20 billion to $30 billion valuation, according to a report by Axios and confirmed by TechCrunch. This leap — potentially more than doubling its previous $10.2 billion valuation set just 16 months ago — signals that investors see Colossal as far more than a scientific curiosity. The company has rapidly evolved into a multi-pronged biotech platform, generating revenue, spinning out high-value startups, and securing government contracts, all while continuing to push the boundaries of genetic engineering.

“

The valuation leap also raises urgent questions: can a company with limited disclosed revenue justify a $30 billion price tag, and what does the spinout strategy signal about founder and investor liquidity?

The reported valuation range is extraordinary for a company that is only five years old and still pursuing a core mission — de-extinction — that remains ethically charged and scientifically unproven in full. Yet Colossal’s expanding portfolio explains the confidence. The company has spun out three independent startups: Breaking, which develops solutions for plastic degradation; Form Bio, a computational biology platform that itself raised $30 million in funding; and Astromech, an AI-driven predictive modeling company focused on biology and life sciences, which was valued at $2 billion in March 2026. Each spinout allows Colossal to commercialize its underlying technologies — such as advanced genomics, machine learning, and synthetic biology — while retaining equity and potentially returning capital to investors.

Colossal has also begun generating revenue, a critical milestone for a company long viewed as a moonshot. CEO Ben Lamm told TechCrunch last year that the business model rests on three revenue streams: conservation technology services, data and software licensing, and potential future product sales. The company has put this into practice, offering its conservation technology to the U.S. government and the government of the United Arab Emirates, the latter of which invested $60 million in the company, according to Wired. These contracts validate the practical, immediate applications of Colossal’s research, such as genetic monitoring tools and bioinformatics for endangered species management.

The core de-extinction pipeline continues to grow. From its 55,000-square-foot headquarters in Dallas, Colossal recently added the bluebuck antelope as its sixth target species in late April 2026. Its nonprofit arm, the Colossal Foundation, struck a partnership with the University of Tasmania in late June 2026 to help protect Tasmanian devils from a contagious facial cancer. These projects demonstrate that the company’s gene-editing and assisted reproduction technologies have real-world conservation applications, not just speculative revivals of long-gone species.